论文部分内容阅读
为探讨小剂量前列腺素Ｅ１（ＰＧＥ１）对重度充血性心力衰竭及内皮素（ＥＴ）水平的影响，对２０例经传统治疗无效的心衰患者小剂量静滴ＰＧＥ１１周，观察治疗前后临床症状、血流动力学及ＥＴ变化。结果发现，临床总有效率为９５％。肺动脉压（ＰＡＰ）、肺毛细血管嵌楔压（ＰＣＷＰ）比治疗前明显下降（４．９３±０．５３对４．００±０．５３ｋＰｓ，Ｐ＜０．０１；３．４７±０．５３对２．５３±０．４０ｋＰａ，Ｐ＜０．０１），体循环阻力指数（ＳＶＲＩ）下降（２０４．８±２１．３对１５０．６±１．３ｋＰａ·ｓ·Ｌ－１·ｍ－２，Ｐ＜０．０５），心指数（ＣＩ）上升（２．２±０．１对２．８±０．２Ｌ·ｍｉｎ－１·ｍ－２，Ｐ＜０．０５）。内皮素明显降低（１５４．５６±４．４０对１１８．１３±２．２４ｎｇ／Ｌ，Ｐ＜０．０１）。提示ＰＧＥ１可降低ＥＴ水平并通过多种机制对心衰产生有益的作用。
To investigate the effect of low-dose prostaglandin E1 (PGE1) on congestive heart failure and endothelin (ET) levels, 20 patients with heart failure who were not treated by conventional therapy were treated with low-dose PGE for 11 weeks. The clinical symptoms, Hemodynamics and ET changes. The results showed that the total clinical effective rate was 95%. Pulmonary arterial pressure (PAP) and pulmonary capillary wedge pressure (PCWP) were significantly lower than those before treatment (4.93 ± 0.53 vs. 4.00 ± 0.53 kPs, P <0.01; 3.47 ± 0.53 (2.53 ± 0.40 kPa, P <0.01), the systemic resistance index (SVRI) decreased (204.8 ± 21.3 vs 150.6 ± 1.3 kPa · s · L -1 · m -2, (P <0.05). The cardiac index (CI) increased (2.2 ± 0.1 vs 2.8 ± 0.2L · min-1 · m-2, P <0.05). Endothelin was significantly decreased (154.56 ± 4.40 vs. 118.13 ± 2.24 ng / L, P <0.01). Tip PGE1 can reduce the level of ET and through a variety of mechanisms on the beneficial effects of heart failure.